Articles On Imugene (ASX:IMU)

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

Imugene takes the road to China with a new cell-therapy collab Heramed strikes its second US deal within two days Beverage play Althea says things go better with THC   From China to Canada to the US, ASX life science plays are striking o...

Anti-infectives house Firebrick Pharma reveals what shareholders think of the company – warts and all Pot play Vitura blooms in the September quarter Recce claims early victory in war against superbugs   In the spirit of being truthful a...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

Investors are stumping up cash for life sciences capital raisings – but the stories need to be well presented After an “incredibly tumultuous” nine months, fundraisings are on track to meet last year’s bumper tally of $2.9 billion Two medt...

ASX 200 closes 0.13% lower on Friday, despite eight of 11 sectors higher  Tech sector leads gains while resource stocks weigh heavily Trigg Minerals continues to progress its proposed US Nasdaq listing    The ASX 200 ended the week lower...

Unloved, forgotten, lonely. The last two days I’ve been talking about the ASX 200’s sluggish performance, but there is something very interesting is brewing beneath the surface. Turns out that there are entire pockets of the small-cap mark...

As the Wise Man sayeth, one should giveth a task to a busy person if one wanteth it done well. Sadly-eth, that doesn’t translate too well into the corporate biotech sphere. Many drug developers proclaim they have ‘multiple shots at goals’ –...

Highlights ASX 200 sees gains led by banks and telecoms Lithium stocks face sharp declines Defensive sectors provide market stability The ASX 200 continued to demonstrate market resilience, with major financial institutions like A...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

Highlights Imugene (IMU) advancing next-generation CAR T therapies Focus on accessibility through allogeneic “off-the-shelf” platforms Expansion into solid tumour treatments underway Chimeric Antigen Receptor T-cell (CAR T) therap...

  Highlights Boss Energy (ASX:BOE), Paladin Energy (ASX:PDN), and Pilbara Minerals (ASX:PLS) remain among the most shorted names Rising short activity observed in Silex Systems (ASX:SLX), Beach Energy (ASX:BPT), and Iluka Resour...

Highlights US policy changes back research on rare diseases Australian biotech firms gain momentum New regulatory clarity benefits orphan drug development Australian biotech companies focused on rare disease therapies are gaining...

  Highlights Several small-cap companies on the ASX displayed notable trading activity within their respective sectors Movements observed in mining, technology, and renewable energy sectors Market interest spans companies l...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

ASX ends flat, overcoming difficult trading session Gold stocks lead gains with index up 3.57pc Info tech and financials slide on US market losses   ASX sticks the landing Although all indicators were pointing to a down day on the ASX to...

Imugene and Chimeric have unveiled further promising results for their Car-T immune-oncology assets Rhythm Biosciences shares soar 18% on kit validation results While investors are picky, equity dollars continue to flow   There’s a long d...

Australia’s S&P/ASX 200 rose 2.36% in July, posting gains of almost 9% so far for CY25 Health care had a dose of good medicine, rebounding 9% to be best performing sector for month Santa Fe Minerals jumps 739% in July after executing d...

Highlights ASX 200 ends higher led by strength in financial and telecom sectors Lithium and uranium stocks slide as commodity prices drop sharply Defensive sectors outperform while major resources retreat The ASX 200 c...

Highlights: ASX 200 ends the day firmer driven by financial and defensive stocks Lithium and uranium sectors underperform amid weak commodity sentiment Major energy and resource players slide despite broader market resilienc...

S&P/ASX 200 Index (ASX: XJO) stocks are lower on Thursday, down 0.13% to 8,726 points. Back in April, the market had a meltdown after US President Donald Trump revealed harsher-than-expected reciprocal tariffs. The US tariffs sho...

Highlights ASX 200 likely to open lower after recent record-setting rally Global markets watch US-EU tariff tensions and central bank cues Commodities trade mixed amid economic uncertainty After notching a record high last week, t...

Good Afternoon and welcome to HotCopper Highlights for Week 29 of the year, I’m Jon Davidson. This segment wrapping up what you were watching and discussing the most on the forums this week, let’s get into it with the most viewed.  Lumos...

On Wednesday, the S&P/ASX 200 Index (ASX: XJO) was out of form and tumbled into the red. The benchmark index fell 0.8% to 8,561.8 points. Will the market be able to bounce back from this on Thursday? Here are five things to watch: ASX 2...

Imugene (ASX: IMU) has received firm commitments for a $37.5 million capital raising to advance the development of off-the-shelf (allogeneic) CAR-T drug azer-cel for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). T...

Lumos Diagnostics says its US distribution deal is worth up to $487 million Impedimed’s US device sales are on a roll Noxopharm treats its first lupus trial patient   In one of the “largest distribution deals of its type” by an ASX-listed...

The ASX has headed into a downturn this Wednesday, mostly thanks to U.S. CPI data from June suggesting Trump’s tariffs are finally having an impact on inflation, but that hasn’t stopped several companies flying on the forums. Listen to t...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a large decline. At the time of writing, the benchmark index is down 0.9% to 8,555.5 points. Four ASX shares that are falling more than most today are listed be...

ASX walks tightrope to slide just 9.7 points All Ords gold sub-index climbs 1.87pc Iron ore prices boost big cap mining stocks ASX slides on renewed tariff threats The ASX 200 finished the day down 0.11%, having plunged a good 20 points i...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Since the February update, an additional 5 patients have been dosed, resulting in 2...

Imugene (ASX:IMU) has been the talk of the HotCopper forums today, with the much-followed immune-oncology researcher seeing two more complete responses (and three partial responses) in its azer-cel CAR T phase 1b trials. Listen to the Ho...

Imugene reports two more ‘complete responders’ in its cell therapy trial Clever Culture Systems shares surge 17% on deal with Big Pharma Novo Nordisk  Compumedics shares vault 24% after full-year update   Imugene (ASX:IMU) will forge ahea...

Highlights: ASX 200 futures down amid global trade tensions and market volatility Donald Trump's tariff escalation targets Canada, EU, and Mexico Silver surges to highest level since 2011; Bitcoin hits new record The ASX 200 is po...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Entering second quarter earnings season in earnest this week for the US will shine a...

ASX biotechs target global cell therapy market, projected to reach ~US$48bn by 2034 Arovella the only ASX-listed biotech delving into CAR iNKT therapies and one of few globally Chimeric aims to ‘break new ground’ in treatment of solid tumo...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

Highlights ASX200 set for softer open amid rising geopolitical tensions  Uranium segment surges despite financials weighing down  Small caps show strength with notable updates across biotech, rare earths, and energy   The Australi...

Highlights ASX-listed companies increasingly pursue secondary trading access through OTC Markets OTC Markets offers a structure supporting US-dollar trading for international equities ASX entities aim to gain US exposure whi...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

Australia’s S&P/ASX 200 rallied 4.20% in May along with global markets as US-tariff tensions eased All of 11 sectors gained in May, led by tech up almost 20% followed by energy and communication services  Dateline Resources surged 978%...

Highlights  ASX200 futures hint at a positive open  Nasdaq posts strongest monthly rally since 2023  Key economic data in focus this week  The Australian share market is poised for a mild uptick at the start of the week, with S&am...

Highlights ASX 200 sees pressure as financial year-end prompts tax-related equity moves Underperforming stocks including Lake Resources (ASX:LKE) and Core Lithium (ASX:CXO) decline further Selling activity intensifies in seg...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin US markets fell last week with tariff tremors re-emerging on Friday with President T...

Good Afternoon and welcome to HotCopper Highlights wrapping up Week 21 of the year, I’m Jon Davidson. In this segment we look at what you’ve been watching and discussing most this week, let’s get into it.  Starting with the most viewed, ...

Anatara has taken a different tack post-trial results, while Chimeric is raising funds and Imugene proposes a share consolidation Heramed falls victim to US healthcare funding cuts D-Day looms for Mayne Pharma holders – or will there be a...

Arovella is one of only a handful of biotechs pursuing CAR-iNKT immunotherapies – and is the only ASX-listed exemplar The “soldiers of the blood stream”, CAR-iNKT cells offer potential advantages including easier off-the-shelf therapies Th...

The US health sector shows signs of stabilising as chaos subsides Immutep will meet with the FDA following “excellent” follow-on trial results When it comes to its sagging share price, Immuron leaves blame-shifting to the defeated Liberals...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

Highlights: Dateline Resources’ share price surged after political attention on rare earth minerals. Peninsula Energy experiences leadership changes amid halted trading and a downgrade. Biotech companies Telix and Dimerix fa...

As it clocks one year returns down -72%, Imugene Ltd (ASX:IMU) this week issued a letter to shareholders confirming shareholders’ worst fears – yes, the company is a high cash burn business. That isn’t this finance journalist – once-des...